Navigation Links
NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
Date:5/13/2008

SOPHIA ANTIPOLIS, France, May 13 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating antihypertensive agents using NicOx' proprietary technology. Three drug candidates have now been selected from the companies' joint research program, of which two have completed initial dose ranging studies in healthy volunteers under the exploratory clinical study paradigm with encouraging results.

Merck plans to conduct a number of clinical studies in hypertensive patients involving single and multiple ascending dosing, prior to the selection of a compound to be advanced into phase 2. The most advanced candidate is now being evaluated in the first of these studies, which is a single ascending dose trial in mild to moderate hypertensive patients. The main objectives of this study are to assess the efficacy, safety, tolerability and pharmacokinetics of single ascending doses of this candidate. Subsequent studies will assess multiple ascending doses.

"The initiation of this series of clinical studies in hypertensive patients is a very important step towards delivering a new treatment paradigm for hypertension, where the medical need remains significant," commented Jacques Djian M.D., NicOx' Cardiometabolic Area Leader. "We believe these drug candidates have considerable potential as improved antihypertensive agents based on their nitric oxide-donating properties and we hope they will deliver a major advance in antihypertensive treatment for patients worldwide."

In July 2007, NicOx announced the initiation of the first in a series of studies in healthy volunteers for the selected candidates (see press release of July 16, 2007). Merck is responsible for funding and performing the development of these compounds going forward.


'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... of its lead molecule, Anatabine Citrate, in ... Clinical, The Translational Pharmaceutics Company, based in the ... early development programs. The Company expects to ... of the third quarter with the Medicines Healthcare products ...
(Date:7/31/2014)... 31, 2014 Touro University California,s College of ... as the recipient of a $150,000 grant by the ... University to increase research and classroom space on its ... for the study of health sciences, and will help ... and interests of our students," said Shelley Berkley ...
(Date:7/31/2014)... July 31, 2014 Catylix, Inc. ( ... ( Milpitas, California ) announced today ... and commercialize new fluorination products and related chemistry. ... benefited from the use of substituents that are ... with polarity to improve binding and bioavailability. Fluorinated ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Touro University California Garners Grant From Long Foundation 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... mental retardation, birth defects, and autism spectrum and ... in New YorkMADISON, N.J., March 17 Quest ... world,s leading provider of diagnostic testing, information and ... genomic hybridization (aCGH) postnatal test is now available ...
... Inc. announced today that it has achieved proof ... Inhibiting Multiple Pathways) kinase platform by designing a ... of both the PI3K (Phosphoinositide-3-kinase) pathway and the ... SF2626 has demonstrated the ability to inhibit both ...
Cached Medicine Technology:Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 2Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 3Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 4Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor 2
(Date:8/1/2014)... Online retailer Disposable Medical Express has ... guarantee on their inventory of Tranquility incontinence care products. ... pads along with other personal care products. , ... a line of incontinence products that you love,” a ... works for you, you shouldn't have to compromise because ...
(Date:8/1/2014)... Stress management can be difficult in this ... concentration and diminish rest and leisure time, stress can mount ... to find a way to manage stress in order to ... “Having a good sense of work-life balance is the key ... founding clinician of SF Custom Chiropractic. “Stress, left unchecked, can ...
(Date:7/31/2014)... Just in time for Washington’s unusually ... is featuring new summertime drink specials on their famed ... locations throughout the season. , A longtime ... customer-nominated Seattle’s best happy hour is well-known for its ... Union location’s 25th anniversary this summer, Duke is now ...
(Date:7/31/2014)... you have asthma, you may have an asthma action plan ... respond to changes and understand when symptoms are getting worse ... you,re doing well, yellow means your asthma has worsened and ... New guidelines are now available to help your allergist steer ... away from the red zone. , "Management of acute loss ...
(Date:7/31/2014)... The 2013 PolyU TSI hit a record ... in 2012. The index measures inbound tourists’ satisfaction ... into an overall index. The 2013 index indicates ... Hong Kong over time. , The index shows ... in Hong Kong are attractions (79.27) and transportation ...
Breaking Medicine News(10 mins):Health News:Disposable Medical Express Offering Low Price Guarantee On Tranquility Products 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3
... -- Could injecting a gene into a patient with ... Physician-scientists are setting out to answer that question in ... severe heart failure. , NewYork-Presbyterian Hospital/Columbia University Medical ... City area where the therapy is currently available. , ...
... will develop training standards and guidelines to ensure ... keeps pace with growth ... To develop first-of-its-kind,guidelines and training standards for ... disease, the Society for,Cardiovascular Angiography and Interventions (SCAI) ...
... Plans to build a second state-of-the-art CCRC across ... MATTHEWS, N.C., June 18 ACTS Retirement-Life,Communities has ... parcel,located near the intersection of Fullwood Lane and ... to add approximately 350 independent,living apartments and single ...
... U.K. study suggests , , WEDNESDAY, June 18 (HealthDay News) ... of anticipating how people might behave during a psychotic ... University of Cambridge, found that patterns of normal brain ... , The researchers compared the brain activity of 15 ...
... in Nation,s 4th Leading Cancer Killer, BETHPAGE, ... Cancer Research, the largest private foundation dedicated,exclusively to ... Request For Proposals (RFP) to identify promising research ... deaths in the United,States., The Lustgarten Foundation,s ...
... the National ... Injury Prevention Program, WASHINGTON, June ... Safety for Seniors Act of 2008,and urges lawmakers to provide ... Center to fully implement this critical,fall prevention initiative., "Millions ...
Cached Medicine News:Health News:First gene therapy for heart failure offered at NewYork-Presbyterian/Columbia 2Health News:SCAI Creates New Council for Rising Interest in Interventional Therapies for Structural Heart Disease 2Health News:SCAI Creates New Council for Rising Interest in Interventional Therapies for Structural Heart Disease 3Health News:ACTS Retirement-Life Communities Signs Land Purchase Agreement on 48-Acre Site in Matthews, North Carolina 2Health News:Brain Activity May Predict Schizophrenia Behavior 2Health News:Lustgarten Foundation Announces 2009 Request for Proposals (RFP) 2Health News:Samarion Praises Congress for Passage of Safety for Seniors Act of 2008 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: